Cargando…

Myostatin and IGF-I signaling in end-stage human heart failure: a qRT-PCR study

BACKGROUND: Myostatin (Mstn) is a key regulator of heart metabolism and cardiomyocyte growth interacting tightly with insulin-like growth factor I (IGF-I) under physiological conditions. The pathological role of Mstn has also been suggested since Mstn protein was shown to be upregulated in the myoca...

Descripción completa

Detalles Bibliográficos
Autores principales: Baán, Júlia Aliz, Varga, Zoltán V, Leszek, Przemyslaw, Kuśmierczyk, Mariusz, Baranyai, Tamás, Dux, László, Ferdinandy, Péter, Braun, Thomas, Mendler, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301667/
https://www.ncbi.nlm.nih.gov/pubmed/25591711
http://dx.doi.org/10.1186/s12967-014-0365-0
_version_ 1782353682900189184
author Baán, Júlia Aliz
Varga, Zoltán V
Leszek, Przemyslaw
Kuśmierczyk, Mariusz
Baranyai, Tamás
Dux, László
Ferdinandy, Péter
Braun, Thomas
Mendler, Luca
author_facet Baán, Júlia Aliz
Varga, Zoltán V
Leszek, Przemyslaw
Kuśmierczyk, Mariusz
Baranyai, Tamás
Dux, László
Ferdinandy, Péter
Braun, Thomas
Mendler, Luca
author_sort Baán, Júlia Aliz
collection PubMed
description BACKGROUND: Myostatin (Mstn) is a key regulator of heart metabolism and cardiomyocyte growth interacting tightly with insulin-like growth factor I (IGF-I) under physiological conditions. The pathological role of Mstn has also been suggested since Mstn protein was shown to be upregulated in the myocardium of end-stage heart failure. However, no data are available about the regulation of gene expression of Mstn and IGF-I in different regions of healthy or pathologic human hearts, although they both might play a crucial role in the pathomechanism of heart failure. METHODS: In the present study, heart samples were collected from left ventricles, septum and right ventricles of control healthy individuals as well as from failing hearts of dilated (DCM) or ischemic cardiomyopathic (ICM) patients. A comprehensive qRT-PCR analysis of Mstn and IGF-I signaling was carried out by measuring expression of Mstn, its receptor Activin receptor IIB (ActRIIB), IGF-I, IGF-I receptor (IGF-IR), and the negative regulator of Mstn miR-208, respectively. Moreover, we combined the measured transcript levels and created complex parameters characterizing either Mstn- or IGF-I signaling in the different regions of healthy or failing hearts. RESULTS: We have found that in healthy control hearts, the ratio of Mstn/IGF-I signaling was significantly higher in the left ventricle/septum than in the right ventricle. Moreover, Mstn transcript levels were significantly upregulated in all heart regions of DCM but not ICM patients. However, the ratio of Mstn/IGF-I signaling remained increased in the left ventricle/septum compared to the right ventricle of DCM patients (similarly to the healthy hearts). In contrast, in ICM hearts significant transcript changes were detected mainly in IGF-I signaling. In paralell with these results miR-208 showed mild upregulation in the left ventricle of both DCM and ICM hearts. CONCLUSIONS: This is the first demonstration of a spatial asymmetry in the expression pattern of Mstn/IGF-I in healthy hearts, which is likely to play a role in the different growth regulation of left vs. right ventricle. Moreover, we identified Mstn as a massively regulated gene in DCM but not in ICM as part of possible compensatory mechanisms in the failing heart.
format Online
Article
Text
id pubmed-4301667
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43016672015-01-22 Myostatin and IGF-I signaling in end-stage human heart failure: a qRT-PCR study Baán, Júlia Aliz Varga, Zoltán V Leszek, Przemyslaw Kuśmierczyk, Mariusz Baranyai, Tamás Dux, László Ferdinandy, Péter Braun, Thomas Mendler, Luca J Transl Med Research BACKGROUND: Myostatin (Mstn) is a key regulator of heart metabolism and cardiomyocyte growth interacting tightly with insulin-like growth factor I (IGF-I) under physiological conditions. The pathological role of Mstn has also been suggested since Mstn protein was shown to be upregulated in the myocardium of end-stage heart failure. However, no data are available about the regulation of gene expression of Mstn and IGF-I in different regions of healthy or pathologic human hearts, although they both might play a crucial role in the pathomechanism of heart failure. METHODS: In the present study, heart samples were collected from left ventricles, septum and right ventricles of control healthy individuals as well as from failing hearts of dilated (DCM) or ischemic cardiomyopathic (ICM) patients. A comprehensive qRT-PCR analysis of Mstn and IGF-I signaling was carried out by measuring expression of Mstn, its receptor Activin receptor IIB (ActRIIB), IGF-I, IGF-I receptor (IGF-IR), and the negative regulator of Mstn miR-208, respectively. Moreover, we combined the measured transcript levels and created complex parameters characterizing either Mstn- or IGF-I signaling in the different regions of healthy or failing hearts. RESULTS: We have found that in healthy control hearts, the ratio of Mstn/IGF-I signaling was significantly higher in the left ventricle/septum than in the right ventricle. Moreover, Mstn transcript levels were significantly upregulated in all heart regions of DCM but not ICM patients. However, the ratio of Mstn/IGF-I signaling remained increased in the left ventricle/septum compared to the right ventricle of DCM patients (similarly to the healthy hearts). In contrast, in ICM hearts significant transcript changes were detected mainly in IGF-I signaling. In paralell with these results miR-208 showed mild upregulation in the left ventricle of both DCM and ICM hearts. CONCLUSIONS: This is the first demonstration of a spatial asymmetry in the expression pattern of Mstn/IGF-I in healthy hearts, which is likely to play a role in the different growth regulation of left vs. right ventricle. Moreover, we identified Mstn as a massively regulated gene in DCM but not in ICM as part of possible compensatory mechanisms in the failing heart. BioMed Central 2015-01-16 /pmc/articles/PMC4301667/ /pubmed/25591711 http://dx.doi.org/10.1186/s12967-014-0365-0 Text en © Baán et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Baán, Júlia Aliz
Varga, Zoltán V
Leszek, Przemyslaw
Kuśmierczyk, Mariusz
Baranyai, Tamás
Dux, László
Ferdinandy, Péter
Braun, Thomas
Mendler, Luca
Myostatin and IGF-I signaling in end-stage human heart failure: a qRT-PCR study
title Myostatin and IGF-I signaling in end-stage human heart failure: a qRT-PCR study
title_full Myostatin and IGF-I signaling in end-stage human heart failure: a qRT-PCR study
title_fullStr Myostatin and IGF-I signaling in end-stage human heart failure: a qRT-PCR study
title_full_unstemmed Myostatin and IGF-I signaling in end-stage human heart failure: a qRT-PCR study
title_short Myostatin and IGF-I signaling in end-stage human heart failure: a qRT-PCR study
title_sort myostatin and igf-i signaling in end-stage human heart failure: a qrt-pcr study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301667/
https://www.ncbi.nlm.nih.gov/pubmed/25591711
http://dx.doi.org/10.1186/s12967-014-0365-0
work_keys_str_mv AT baanjuliaaliz myostatinandigfisignalinginendstagehumanheartfailureaqrtpcrstudy
AT vargazoltanv myostatinandigfisignalinginendstagehumanheartfailureaqrtpcrstudy
AT leszekprzemyslaw myostatinandigfisignalinginendstagehumanheartfailureaqrtpcrstudy
AT kusmierczykmariusz myostatinandigfisignalinginendstagehumanheartfailureaqrtpcrstudy
AT baranyaitamas myostatinandigfisignalinginendstagehumanheartfailureaqrtpcrstudy
AT duxlaszlo myostatinandigfisignalinginendstagehumanheartfailureaqrtpcrstudy
AT ferdinandypeter myostatinandigfisignalinginendstagehumanheartfailureaqrtpcrstudy
AT braunthomas myostatinandigfisignalinginendstagehumanheartfailureaqrtpcrstudy
AT mendlerluca myostatinandigfisignalinginendstagehumanheartfailureaqrtpcrstudy